[go: up one dir, main page]

DE69632062D1 - Kontinuierliche, niedrigdosierte zytokine-infusionstherapie - Google Patents

Kontinuierliche, niedrigdosierte zytokine-infusionstherapie

Info

Publication number
DE69632062D1
DE69632062D1 DE69632062T DE69632062T DE69632062D1 DE 69632062 D1 DE69632062 D1 DE 69632062D1 DE 69632062 T DE69632062 T DE 69632062T DE 69632062 T DE69632062 T DE 69632062T DE 69632062 D1 DE69632062 D1 DE 69632062D1
Authority
DE
Germany
Prior art keywords
cytokine
low
continuous
infusion therapy
dose cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69632062T
Other languages
English (en)
Other versions
DE69632062T2 (de
Inventor
L Cutler
B Affrime
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21719457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69632062(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69632062D1 publication Critical patent/DE69632062D1/de
Application granted granted Critical
Publication of DE69632062T2 publication Critical patent/DE69632062T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE1996632062 1995-11-02 1996-10-31 Kontinuierliche, niedrigdosierte zytokine-infusionstherapie Expired - Lifetime DE69632062T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US613095P 1995-11-02 1995-11-02
US6130P 1995-11-02
PCT/US1996/017085 WO1997016204A1 (en) 1995-11-02 1996-10-31 Continuous low-dose cytokine infusion therapy

Publications (2)

Publication Number Publication Date
DE69632062D1 true DE69632062D1 (de) 2004-05-06
DE69632062T2 DE69632062T2 (de) 2004-11-18

Family

ID=21719457

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1996632062 Expired - Lifetime DE69632062T2 (de) 1995-11-02 1996-10-31 Kontinuierliche, niedrigdosierte zytokine-infusionstherapie

Country Status (12)

Country Link
US (1) US6461605B1 (de)
EP (1) EP0858343B1 (de)
JP (2) JP2000507917A (de)
AT (1) ATE262920T1 (de)
AU (1) AU7473096A (de)
CA (2) CA2329474C (de)
DE (1) DE69632062T2 (de)
DK (1) DK0858343T3 (de)
ES (1) ES2214551T3 (de)
MX (1) MX9803448A (de)
PT (1) PT858343E (de)
WO (1) WO1997016204A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69632062T2 (de) 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU751898B2 (en) * 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
AU754002B2 (en) * 1998-03-26 2002-10-31 Merck Sharp & Dohme Corp. Formulations for protection of peg-interferon alpha conjugates
EP0956861B1 (de) * 1998-05-15 2002-04-24 Schering Corporation Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind
WO1999064016A1 (en) * 1998-06-08 1999-12-16 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
EP1113794A2 (de) * 1998-09-14 2001-07-11 Vertex Pharmaceuticals Incorporated Verwendung von mycophenolsäure und mycophenolsäurederivate zur behandlung von viruserkrankungen
EP1140142A2 (de) * 1998-12-22 2001-10-10 Schering Corporation Interleukin 10 behandlung von hepatitis c virusinfektionen
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR0010593A (pt) * 1999-05-04 2002-02-13 Schering Corp Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
AU2001264563A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
RU2003102887A (ru) * 2000-08-02 2004-07-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Усовершенствованная противовирусная и противоопухолевая химиотерапии путем введения эритропоэтина
HUP0301444A3 (en) * 2000-10-18 2007-05-29 Schering Corp The use of ribavirin-pegylated interferon alfa for the preparation of pharmaceutical compositions for the treatment of hcv infection
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
KR20050042035A (ko) * 2001-11-02 2005-05-04 제네바 파마슈티컬즈, 인크. 신속 용해성 고부하 리바비린 조성물의 제조 방법
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
EP2277889B1 (de) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusionsproteine von Albumin und Interferon beta
CA2473163C (en) * 2002-01-17 2011-12-06 Polymun Scientific Immunbiologische Forschung Gmbh Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
JP4629964B2 (ja) * 2003-09-12 2011-02-09 株式会社林原生物化学研究所 ウシの消化器疾患治療剤
US8034764B2 (en) * 2003-10-21 2011-10-11 Medtronic Minimed, Inc. Modulation of SOCS expression in therapeutic regimens
ES2294589T3 (es) 2004-04-29 2008-04-01 F. Hoffmann-La Roche Ag Variacion de la secuencia nucleosida de ns5a como marcador.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2175865A4 (de) 2007-07-25 2012-01-11 Biolex Therapeutics Inc Interferon-arzneiprodukte mit kontrollierter freisetzung und behandlung von hcv-infektionen damit
WO2009046369A2 (en) * 2007-10-05 2009-04-09 Medtronic, Inc. Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010009762A1 (en) * 2008-07-23 2010-01-28 United Technologies Ut Ag Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection
WO2010033443A1 (en) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
EP2459211A1 (de) 2009-07-31 2012-06-06 Medtronic, Inc. Kontinuierliche subkutane verabreichung von interferon an hepatitis-c-patienten
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
CA2779244A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
IL262802B2 (en) 2016-05-16 2025-04-01 Intarcia Therapeutics Inc Glucagon receptor selective polypeptides and methods of using them
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4140761A (en) 1977-04-11 1979-02-20 The United States Of America As Represented By The Department Of Health, Education & Welfare Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4774091A (en) 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
IL76591A0 (en) 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
NZ217844A (en) 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
WO1993020835A1 (en) * 1992-04-14 1993-10-28 Schering Corporation Treatment of hepatitis with gm-csf
ATE163860T1 (de) * 1992-08-19 1998-03-15 Schering Corp Methode zur inhibition von hiv-replikation mittels il-4
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
MX9307733A (es) * 1992-12-23 1994-06-30 Schering Corp Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo.
CN1072961C (zh) 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
DE69632062T2 (de) 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5849800A (en) 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C

Also Published As

Publication number Publication date
CA2236591C (en) 2012-01-03
JP2000507917A (ja) 2000-06-27
WO1997016204A1 (en) 1997-05-09
AU7473096A (en) 1997-05-22
CA2329474C (en) 2002-02-26
US6461605B1 (en) 2002-10-08
CA2329474A1 (en) 1997-05-09
DK0858343T3 (da) 2004-05-10
ATE262920T1 (de) 2004-04-15
EP0858343A1 (de) 1998-08-19
DE69632062T2 (de) 2004-11-18
CA2236591A1 (en) 1997-05-09
JP2003246750A (ja) 2003-09-02
ES2214551T3 (es) 2004-09-16
MX9803448A (es) 1998-09-30
PT858343E (pt) 2004-07-30
EP0858343B1 (de) 2004-03-31

Similar Documents

Publication Publication Date Title
DE69632062D1 (de) Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
RO115700B1 (ro) Metodă de tratament cu interferon
NZ309217A (en) Ribavirin and interferon alpha for the treatment of hepatitis C
GEP20002146B (en) Therapeutic Peptide Derivatives
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
IL130785A0 (en) Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same
WO2005039622A3 (en) Modulation of socs expression in the therapeutic regimens
FI954127A0 (fi) Menetelmä C-hepatiitin hoitamiseksi interferonihoitoon reagoimattomissa potilaissa
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
HK1056117A1 (en) Treatment of hepatitis C with thymosin and pegylated interferon
UA49320A (uk) Спосіб лікування пневмоцистозу у хворих на хронічний бронхіт
RU94037731A (ru) Способ лечения рассеянного склероза

Legal Events

Date Code Title Description
8363 Opposition against the patent